Vera Therapeutics' 2025 net loss wider than expectations

Reuters02-26
Vera <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' 2025 net loss wider than expectations

Overview

  • Biotechnology firm's 2025 net loss of $299.6 mln missed analyst expectations

  • Loss per share for 2025 missed analyst estimates

  • Company preparing for potential atacicept launch in mid-2026, pending FDA approval

Outlook

  • Company expects FDA approval of atacicept by July 7, 2026

  • Vera Therapeutics plans commercial launch of atacicept in mid-2026

  • Company expects initial results from Phase 2 trial in 1H 2026

Result Drivers

  • POSITIVE TRIAL RESULTS - Phase 3 trial of atacicept showed significant reduction in proteinuria, supporting potential FDA approval

  • FDA PRIORITY REVIEW - FDA granted priority review to atacicept BLA with PDUFA date set for July 7, 2026

  • STRONG FINANCIAL POSITION - Equity and debt financings raised $800 mln, funding operations beyond atacicept's potential approval and launch

Company press release: ID:nGNXbrDFgs

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY EPS

Miss

-$4.66

-$4.55 (13 Analysts)

FY Net Income

Miss

-$299.62 mln

-$292.51 mln (10 Analysts)

FY Operating Income

Miss

-$315.47 mln

-$305.86 mln (10 Analysts)

FY Operating Expenses

$315.47 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Vera Therapeutics Inc is $73.00, about 75.1% above its February 25 closing price of $41.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment